Medication info
Sitaphomin Alpha Tablet 50/850 mg

Sitaphomin Alpha Tablet 50/850 mg

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.7mg / 1 tabletMetformin Hydrochloride with Colloidal Anhydrous Silica›858.5mg / 1 tablet
Manufacturer / importer
Daehan New Pharm Co., Ltd.
Appearance
Pink oval film-coated tablet
Packaging
30 tablets per box [10 tablets/PTP x 3]
Approval status
Active

MFDS item code 202200113 · Approved 2022.01.06 · Insurance code 669908250

Summary

Main use
Improvement of blood glucose control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this product for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This product is generally taken 2 times daily with food. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this product should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no previous history of antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose of this product is 1 tablet of 50/500 mg 2 times daily. The dose may be increased to 1 tablet of 50/1000 mg 2 times daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this product (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this product is sitagliptin 50 mg 2 times daily (total daily dose of 100 mg) and the patient's existing metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this product may start at their existing doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with concomitant metformin and sulfonylurea therapy, metformin and insulin therapy, or metformin and thiazolidinedione therapy: The initial dose of this product is sitagliptin 50 mg 2 times daily (total daily dose of 100 mg). The initial dose of metformin should be determined based on the patient's blood glucose level and existing dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When this product is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching to this product in patients previously treated with other oral antihyperglycemic agents. Any change in treatment for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This product may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who have no other symptoms that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this product, since the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg 2 times daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this product should be discontinued immediately. Patients with hepatic impairment This product should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).

Ingredients

Manufacturer
Daehan New Pharm Co., Ltd.

Efficacy & effects

Improvement of blood glucose control in type 2 diabetes mellitus

  • Type 2 diabetes
  • difficulties in blood sugar control
View approved original text

This medication is used as a treatment to assist in the blood sugar control of patients with type 2 diabetes and plays a role in supporting dietary and exercise therapy. It can be administered solely to patients who are starting diabetes medication for the first time, and is used in combination with metformin or sitagliptin if blood sugar control is insufficient with monotherapy alone. Additionally, if blood sugar control is inadequate with combination therapy of metformin and sulfonylureas or thiazolidinediones, this medication can be added to enhance efficacy. It also improves treatment effectiveness when combined with insulin and metformin if blood sugar control is challenging. Therefore, it is used in a variety of combinations to enhance blood sugar control.

How to take

Adult dose

The dose of this product for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This product is generally taken 2 times daily with food. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this product should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no previous history of antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose of this product is 1 tablet of 50/500 mg 2 times daily. The dose may be increased to 1 tablet of 50/1000 mg 2 times daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this product (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this product is sitagliptin 50 mg 2 times daily (total daily dose of 100 mg) and the patient's existing metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this product may start at their existing doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with concomitant metformin and sulfonylurea therapy, metformin and insulin therapy, or metformin and thiazolidinedione therapy: The initial dose of this product is sitagliptin 50 mg 2 times daily (total daily dose of 100 mg). The initial dose of metformin should be determined based on the patient's blood glucose level and existing dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When this product is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching to this product in patients previously treated with other oral antihyperglycemic agents. Any change in treatment for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This product may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who have no other symptoms that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this product, since the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg 2 times daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this product should be discontinued immediately. Patients with hepatic impairment This product should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).

Precautions

This medication contains both sitagliptin and metformin and is used for blood sugar control in patients with type 2 diabetes. During the course of taking this medication, severe allergic reactions may occur, so if symptoms such as rash, hives, difficulty breathing, or swelling of the face or neck develop, you should immediately stop taking the medication and consult a doctor. There is also a risk of pancreatitis, which is inflammation of the pancreas, so if symptoms such as sudden abdominal pain, nausea, vomiting, or fever occur, immediate medical attention should be sought. Due to the metformin component, lactic acidosis, a rare but serious metabolic abnormality, may occur. If symptoms such as muscle pain, weakness, difficulty breathing, abdominal pain, or unusual drowsiness occur, you should inform your doctor immediately. This medication should not be administered to patients with significantly reduced kidney function, severe liver disease, acute heart conditions, severe infections, or dehydration. Patients scheduled to undergo tests with radiologic contrast agents should discontinue the use of this medication for a certain period before and after the examination, so it is crucial to discuss this with healthcare professionals. It is safer for women who are pregnant or may become pregnant, as well as lactating women, to avoid taking this medication. During treatment, there may be symptoms of hypoglycemia, such as extremely low blood sugar, therefore irregular eating, excessive exercise, and alcohol consumption should be avoided. If symptoms of hypoglycemia (dizziness, cold sweat, shaking, etc.) occur, immediate action should be taken. Regular tests of kidney function and blood tests should be conducted, and since vitamin B12 levels may decrease, supplementation may be necessary. If undergoing surgery, this medication should be temporarily discontinued 48 hours before the procedure, and resumed only after normal oral intake is restored and kidney function is confirmed. This medication may interact with other hypoglycemic agents, antihypertensives, diuretics, etc., so if you are taking other medications, it is essential to inform your doctor or pharmacist. In the event of an overdose, immediate medical attention should be sought, and blood dialysis may be beneficial. It is advisable to avoid alcohol consumption while taking this medication, and if sudden changes in symptoms or adverse reactions are suspected, immediately consult a physician.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory tract infection
  • headache
  • nausea
Show 22 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • constipation
  • severe and disabling arthralgia
  • vesicular pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • dermatitis
  • loss of appetite
  • weight loss
  • dyspnea
  • unstable angina
  • dizziness
  • acute renal failure
  • decreased appetite
  • gastrointestinal disturbances
  • itching

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air ingress, at a temperature between 1 and 30 degrees Celsius. Storing it this way will ensure the safe maintenance of the medication's effectiveness.

Appearance and packaging

Appearance

Pink oval film-coated tablet

Package unit

30 tablets per box [10 tablets/PTP x 3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.